Ceregumil Kids Vitamins Algae Omega 3 EPA DHA Liquid Vitamins and Minerals w/ TERRIFIC Cherry Taste + Vitamin C, D3, B6, B12 (Methylcobalamin) for Physical and Mental Development, UNIQUE w/ High Grade Royal Jelly to Help Fight Stress and Fatigue to Help Maintain Normal Growth and Development, Immune System Booster and Nervous System – 250mL – (Pekes) Reviews

November 8, 2016 by  
Filed under Latest Products

Hello, this is your first time visiting our site!

Please enjoy, and signup for our discount coupon notification!

428da Vitamins 51xvEdF2IlL. SL160  Ceregumil Kids Vitamins Algae Omega 3 EPA DHA Liquid Vitamins and Minerals w/ TERRIFIC Cherry Taste + Vitamin C, D3, B6, B12 (Methylcobalamin) for Physical and Mental Development, UNIQUE w/ High Grade Royal Jelly to Help Fight Stress and Fatigue to Help Maintain Normal Growth and Development, Immune System Booster and Nervous System   250mL   (Pekes) Reviews

  • • Great tasting kid's liquid multivitamin, 100% NON-GMO, absorbs quickly (even if your child is not in the best health status) by the body and provides nutrients growing children desperately need but rarely get.
  • • HIGH OMEGA 3 DHA content for focus, attention and brain health. From algae so no bad taste, fights overfishing and gives the same benefits as fish.
  • • WITH ROYAL JELLY for Healthy Growth and.Boosts Immune System, Healthy Bone & Energy, Helps provide a first-line defense for a healthy lifestyle.
  • • Breakthrough formula uses naturally absorbing nutrients and vitamins to ensure your kids receive optimal nourishment + HIGH POTENCY B12 for mental focus and energy balance.
  • • ALL NATURAL INGREDIENTS - 8 ESSENTIAL NUTRIENTS + HIGH POTENCY B12 for mental focus and energy balance.

Vitamin D is important to kids. It doesn't just develop strong teeth and bones; it's an important part of their day. That's why it's so important we help our children get the vitamins they need for their bodies and their mind. With Ceregumil Kids, you can get your recommended dose of Vitamin D with just one spoonful. Plus we know that no kid likes plain medicine, that's why Ceregumil Kids comes in a delicious cherry flavor. With all natural ingredients like Royal Jelly and honey, your child will

List Price: $ 24.99
Special-Price Today: $ 25.99

Full Product Details Here

More Vitamins Products

Organic Turmeric Formula

Prenatal DHA Vitamins – Best Pregnancy Care Supplement – Made With Vitamin D3, Omega 3 & EPA for Brain & Eye Health – 100% Natural Formula for Healthy Baby Development – 180 Softgels Reviews

June 21, 2016 by  
Filed under Latest Products

365bf Supplements 516M5u5TDyL. SL160  Prenatal DHA Vitamins   Best Pregnancy Care Supplement   Made With Vitamin D3, Omega 3 & EPA for Brain & Eye Health   100% Natural Formula for Healthy Baby Development   180 Softgels Reviews

  • For a Healthy & Happy Pregnancy - Zenwise Health understands that nothing is more important to a mother than their child's well-being. Our Prenatal DHA supplements are nourishing vitamins that support pregnant or nursing mothers to ensure their beautiful bundles of joy will receive the best nourishment for healthy development before and after the fetal stage!
  • What is DHA? How Can It Help? - Omega-3 DHA is a wondrous fatty acid that has been shown to play a major role in the infant brain, eye and nervous system development. Plus, it also keeps both hair and skin soft and smooth! So, give you and your baby the ultimate advantage with a powerful supplement that contains 500mg of Omega-3 DHA per softgel.
  • For Healthy Bone Growth - Zenwise Health added 2,000 IU of Vitamin D3 in this prenatal blend to promote optimal skeletal health for your boy or girl, and has also been shown to help reduce pregnancy complications for expecting moms.
  • 100% Natural Ingredients - Whether it's before, during or after pregnancy or lactation, women and children will enjoy amazing benefits after using this pregnancy supplement thanks to the carefully-crafted ingredients found in this formula. And best of all, it's an unflavored formula for mothers with sensitive palates. That means no fish burps or bitter aftertaste!
  • A Supplement You Can Trust - Zenwise Health proudly formulates this Prenatal DHA supplement in an FDA-registered facility that is NSF and GMP certified, and all products are manufactured in the USA.

Give Birth to a Healthy and Beautiful Baby With Zenwise Health's Prenatal DHA Supplement For a healthy and happy pregnancy, choose this premium vitamin that keeps mothers and infants as healthy and happy as can be: - 2000 IU of Vitamin D3 - 150mg of EPA - 450mg of DHA - No filler ingredients - Unflavored formula What are the benefits, you ask? Priceless nourishment for both you and your pride and joy: - Supports skeletal development for babies - Keeps skin healthy an

List Price: $ 15.97
Special-Price Today: $ 15.97

Full Product Details Here

OrganicIndiaUSA.com

Weight Loss Development – Apple Cider Vinegar Pills – Natural Body Cleanser For Detox And Diet – Supports Digestive System And Supplement Great Source Of Vitamin B – 90 Capsules

November 17, 2015 by  
Filed under Latest Products

1ead8 Body Detox 414lCK58C2BL. SL160  Weight Loss Development   Apple Cider Vinegar Pills   Natural Body Cleanser For Detox And Diet   Supports Digestive System And Supplement Great Source Of Vitamin B   90 Capsules

  • EXCELLENT choice for natural weight management and weight control. Thermogenic effects and blood sugar control helps burn belly fat.
  • CHARGED with Spirulina and Lecithin. Perfect for cleansing, alkalizing, detox, diets and supports an optimal pH balance. The antioxidants are immune system boosters and promotes better health.
  • ADDED benefits from Kelp and Bromelain make these tablets even more powerful. For lowering cholesterol and liver cleanse.
  • EXECUTED and produced in USA in GMP certified lab guarantees optimal quality products and highest purity.
  • COMES with WEIGHT LOSS eBook & access to exclusive Weight Loss & Fat Burning Concierge program! 100% Customer Satisfaction and Money Back Lifetime Guarantee.

**Time to lose weight? Time to get toned and slim? Get a healthy, cleaned and fresh body? Our premium Apple Cider Vinegar a perfect supplement for you.** **See images above.** **Our Apple Cider Vinegar is a great weight loss fat burning product. It is developed to support detoxes and cleanses as well as promoting a strong immune system and good health during dieting and weight management phases. It also supports food digestion. There are no known harmful side effects from taking this natural sup

List Price: $ 39.97
Special-Price Today: $ 49.97

Full Product Details Here

Related Body Detox Products

Organic Neem Formula

Resort Savers Inc. In Negotiations To Acquire Shenzhen Amuli Industrial Development Co. Ltd. Generating Over $3.6M USD in Annual Profits

July 18, 2015 by  
Filed under Allergy Tips

;

Resort Savers, Inc. (OTCBB: RSSV), a strategic investment and development company, announced today that is in negotiations to acquire 100% of Shenzhen Amuli Industrial Development Co. Ltd. (Amuli). Based in Shenzhen, Amuli is a large producer of the health beverage drink Kvass and generates over $ 3.6M USD in annual profits. With a production facility expansion forecasted to generate an additional $ 16M USD in annual sales, Amuli represents a major acquisition opportunity for RSSV.

;

Amuli?s flagship Kvass targets China?s booming health drink market, which is expected to reach $ 20 Billion USD by 2017. Kvass is a traditional Slavic drink made from fermenting black or rye bread along with other fruits and berries. Kvass?s health benefits have been well known for centuries, lowering the Ph to kill harmful bacteria. Kvass is high in Vitamin B and has a distinctly bubbly and tangy taste.

;

Zhou Gui Bin, President of RSSV said, ?By wholly acquiring Amuli and consolidating its operations, RSSV is taking a major step in its growing its portfolio of high demand, revenue generating assets. With this acquisition, RSSV is entering the booming Chinese health beverage industry that is growing at over 20% a year. Amuli?s Kvass is made by fermenting wheat and honey, giving it a sweeter flavor, which is more desirable to Chinese tastes. The Chinese people are becoming increasingly health conscious and Amuli?s Kvass provides an easy and effective way to boost daily health.?

;

Zhou continued, ?Amuli?s production facility expansion will allow RSSV to capture increasing market share in this booming segment of the economy. Amuli is building new facilities in Shenzhen and Beijing, representing an extensive operational increase that should generate an additional $ 16M USD in annual sales. Also, due to the substantial demand growth, the market has seen increasing M&A activity in China?s health and functional beverage market, with major multinationals acquiring China based beverage producers. This M&A activity has generated several Billion dollars in transactions, opening up major opportunities for RSSV to capitalize on this merger and acquisition market space.?

;

Zhou concluded, ?Amuli is a major acquisition opportunity for RSSV, which will allow us to enter China?s growing health beverage market. Kvass has been consumed for centuries and has numerous health benefits, benefits RSSV wants to bring to the Chinese people. This acquisition not only proves our commitment to building a profitable asset portfolio for our shareholders, but to improving the health of China.?

;

?In other news, we expect close the acquisition of Kashi Jinju Color Printing Packaging Co. Ltd. in sixty days upon completion of Kashi?s audit, which will add $ 9 Million USD in assets to our books. As you can see, RSSV is on its way to establishing itself as a premier strategic investment and development company and we are very excited for the future.?

;

Sources: ;
http://www.wantchinatimes.com

;

About Resort Savers, Inc. http://www.resortsaversinc.com ;
Resort Savers, Inc. (OTCBB: RSSV) is a strategic acquisition and development company focused on identifying and acquiring high demand, revenue-generating assets. RSSV is currently developing and investing in the oil and gas industry, real estate development and is set to enter the cardboard packaging industry by acquiring Kashi.

;

Contact: Rex Cheung 852-2531-3511

;

Forward-Looking Statements ;
Except for the historical matters contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. This release should be read in conjunction with Resort Savers' Annual Report on Form 10-K and its other filings with the U.S Securities and Exchange Commission through the date of this release, which identifies important factors that could affect the forward-looking statements in this release.

; ; ; ; ;

    FIBER HARMONYô - A revolutionary Certified Organic Tri-Active Fiber Blend for Digestive Health.

    Nationally-Recognized Youth Development Organization and Award-Winning Public Education Campaign Team Up To Prevent Youth Tobacco Use

    July 9, 2015 by  
    Filed under Allergy Tips

    ; ;

    Legacy and Wyman are building a 7-lesson curriculum and pilot program to educate and engage students to prevent youth tobacco use and substance abuse.

    ; ;

    Legacy and Wyman announced today a new collaboration to educate and engage students to prevent youth tobacco use and substance abuse. The two organizations will create a specialized curriculum to reach young people participating in Wyman?s innovative Teen Outreach Program? (TOP?).

    ;

    Legacy, the national public health organization best known for its award-winning truth? youth tobacco prevention campaign, and Wyman, a Saint Louis-based nonprofit with more than 117 years? experience helping teens from economically disadvantaged circumstances, have agreed to collaborate on a one-year project to develop and test a tobacco control and substance abuse supplement to Wyman?s successful youth programming.

    ;

    TOP is a results-driven youth development approach that transforms teens and communities by empowering teens with the tools and opportunities needed to avoid risky behaviors and build a foundation of healthy behaviors, life skills and a sense of purpose.

    ;

    ?Legacy can?t end the tobacco epidemic without partners like Wyman who share our commitment to empowering young people and to achieving health equity,? said Robin Koval, CEO and President of Legacy. ?Together we will build on the TOP program and take on the challenge of ending tobacco?s reign as the leading preventable cause of death in the United States.?

    ;

    Via a grant from Legacy to Wyman, the organizations are building a seven-lesson tobacco and substance abuse curriculum to strengthen youth knowledge about tobacco, change youth attitudes toward tobacco and engage young people as tobacco control activists. Two sites within Wyman?s National Network will pilot the curriculum. More than 400 teens will participate in the pilots that will launch this fall. A third party evaluator will assess pilot outcomes and publish results in 2016.

    ;

    TOP uses community service learning to help teens understand local issues and exercise the self-confidence, voice, advocacy, decision-making and priority-setting skills they develop as part of the program. The pilot will engage teens in tobacco control service learning experiences as well as participant-led local youth activism projects.

    ;

    ?This is a truly compelling opportunity to add another level of health advocacy to our work,? said Joe Miller, Wyman?s Senior Vice President of Partnerships and External Affairs. ?This collaboration will further improve the lives and potential of TOP participants and trigger a positive ripple effect in communities where youth are most at risk of tobacco use.?

    ;

    TOP is offered to teens in grades six through 12 at in-school, after-school and community settings via 68 partners and 300 providers in urban and rural environments nationwide. One of the most successful, cost-effective and highly-respected, evidence-based programs for teens in the U.S., TOP has been proven to reduce the risk of problem behavior and to increase healthy choices. To date, more than 600,000 young people have participated in Wyman?s programs.

    ;

    Since its inception, Legacy has recognized the importance of youth activists in the fight against tobacco use. Legacy actively supports the efforts of young people who are ready to make a difference with programming that includes fellowships, hands-on training and expert-led presentations to develop the next generation of youth and young adult tobacco control leaders.

    ;

    Legacy

    ;

    Legacy envisions an America where tobacco is a thing of the past, where all youth and young adults reject tobacco use. Legacy?s proven-effective and nationally recognized public education programs include truth?, the national youth smoking prevention campaign that has been cited as contributing to significant declines in youth smoking; EX?, an innovative public health program designed to speak to smokers in their own language and change the way they approach quitting; and research initiatives exploring the causes, consequences and approaches to reducing tobacco use. Located in Washington, D.C., the foundation was created as a result of the November 1998 Master Settlement Agreement (MSA) reached between attorneys general from 46 states, five U.S. territories and the tobacco industry. To learn more about Legacy?s life-saving programs, visit http://www.LegacyForHealth.org. Follow us on Twitter @legacyforhealth and on Facebook at http://www.Facebook.com/Legacy.

    ;

    Wyman Center

    ;

    Wyman, a 501(c) 3 not-for-profit and proud member of the United Way, partners with communities to provide teens with the support and opportunities they need to thrive in life. Originally founded in 1898, Wyman?s mission is to enable teens from economically disadvantaged circumstances to lead successful lives and build strong communities. To learn more visit: http://wymancenter.org/ or http://teenoutreachprogram.com/. Follow us on Twitter @WymanCenter and on Facebook at http://www.Facebook.com/WymanCenter.

    ; ; ; ; ;

      Organic Herbal Coffee, Organic Teeccino Maya set

      Rett Syndrome Research Trust Awards $5.8 Million to Advance the Development of Treatments and Cures for Rett Syndrome and MECP2 Disorders

      February 5, 2015 by  
      Filed under Allergy Tips

      Trumbull, CT (PRWEB) February 03, 2015

      Today the Rett Syndrome Research Trust (RSRT) announced research investments of $ 5.8 million awarded in 2014. RSRT?s sole and urgent goal is to abolish Rett Syndrome and related disorders. To that end, RSRT has awarded $ 25 million to research since its launch in 2008.

      ;

      Rett Syndrome is caused by mutations in a gene called MECP2 that result in a cascade of devastating symptoms that worsen over time. These symptoms begin to manifest in early childhood and leave Rett sufferers dependent on 24-hour-a-day care for the rest of their lives.

      ;

      The 2014 awards support projects ranging from basic science to drug development and clinical trials. Each project was selected via a rigorous peer review process that assures the highest scientific integrity. To receive funding, every project was required to demonstrate that it has the potential to advance the development of treatments and cures.

      ;

      Highlights of RSRT?s 2014 awards: ;

      ; ????Funding of $ 1.3 million was awarded to Case Western Reserve University and the Cleveland Clinic for a Phase 2 dose escalating, placebo controlled clinical trial of low-dose ketamine for the treatment of Rett Syndrome. The study is being led by David Katz, Ph.D., Professor of Neurosciences and Psychiatry at Case Western Reserve University School of Medicine and Daniel I. Sessler, M.D., Michael Cudahy Professor and Chair, Department of Outcomes Research at the Cleveland Clinic. Studies undertaken by Dr. Katz showed that low-dose ketamine can reverse deficits in brain activity in mouse models of Rett Syndrome in conjunction with significant improvements in neurological function, including breathing. Ketamine, a drug that has historically been used for sedation and anesthesia, has recently generated much enthusiasm for its ability to rapidly reverse major depression at low, sub-anesthetic, doses. This trial will determine the effect of single doses of ketamine on breathing abnormalities and overall clinical severity, as well as EEG abnormalities, visually evoked potentials, and repetitive behaviors.

      According to Drs. Katz and Sessler, ?This trial evolved as a dynamic collaboration among basic scientists, clinicians, and clinical trialists including expert advisers recruited by RSRT. We are grateful to RSRT for fostering this collaborative spirit and providing the support necessary to make this trial a reality.? Co-investigators include Tom Frazier, Ph.D, Director of the Cleveland Clinic Center for Autism; Sumit Parikh, M.D., Director of the Cleveland Clinic Neurogenetics, Metabolic & Mitochondrial Disease Program; and Edward J. Mascha, Ph.D., Senior Biostatistician in the Department of Outcomes Research at the Cleveland Clinic.

      ;

      ????Aleksandra Djukic, M.D., Ph.D., medical director of the Tri-State Rett Syndrome Center at the Children?s Hospital at Montefiore was awarded $ 403,000 to conduct a Phase 2 dose escalating open label clinical trial of lovastatin, a cholesterol lowering medication. The scientific basis for this trial stems from experiments conducted in the lab of mouse geneticist, Monica Justice, Ph.D., who identified the cholesterol pathway as a potential avenue to improve Rett symptoms. The trial will determine the effect of lovastatin on gait, respiratory function, cognition, EEG and severity of the disease.

      ?Cholesterol is vitally important for brain function. In fact, although the brain is only 2-3% of total body weight, it contains and makes 25% of the body?s cholesterol. Dr. Justice?s work suggests that elevated cholesterol levels in the brain may play a role in Rett symptoms. Our trial will test the hypothesis that reducing cholesterol in the brain will lead to symptom improvement,? stated Dr. Djukic.

      ;

      Dr. Djukic recently concluded an open label Phase 2 trial testing safety and efficacy of copaxone in Rett Syndrome. The data is currently being analyzed.

      ;

      The ketamine and lovastatin trials will begin recruitment shortly. Information will be available on the RSRT website.

      ;

      ????Individuals with Rett display a broad spectrum of symptom severity. Some girls can run, have a degree of hand use and can speak in short sentences while others cannot even sit or hold their head up. One reason for this variation is the child?s own unique genetic makeup ? in other words, variations in other genes that impact the severity of the Rett mutation. Monica Justice, Head and Senior Scientist in the Genetics & Genome Biology program at The Hospital for Sick Children in Toronto, has undertaken a mutagenesis screen to identify these modifying genes with a focus on suppressors of symptoms, hoping that they might suggest a therapeutic pathway. The first suppressor she identified, squalene epoxidase, led to the lovastatin trial described above. The screen is currently at the halfway point with 12 modifiers identified. RSRT has awarded Dr. Justice $ 716,000 in additional funding to complete the screen. This brings RSRT?s total commitment to the project to $ 2.3 million.

      ?Monica Coenraads approached me a number of years ago asking how I would identify modifiers. I thought that an unbiased suppressor screen using a mouse supermutagen would be the most effective approach, and was timely with the advent of new genome sequencing technologies. Such an approach was considered very risky, requiring funding through a forward-looking organization such as the RSRT. It has been extremely rewarding to move from the development of a concept?to isolating modifiers that were unexpected?to a clinical trial. Our ongoing screen is much easier and quicker now as technologies advance. My hope is that many more trials will come from the continuing screen,? says Dr. Justice.

      ;

      ????Two additional projects are aimed at awakening a healthy but silenced back-up copy of the mutated Rett gene. If the flawed gene could be replaced by reawakening its silenced counterpart we could conceivably reverse Rett symptoms. Currently pursuing this approach with RSRT funding are labs at the University of North Carolina at Chapel Hill, the University of Massachusetts, Harvard University, and Fred Hutchinson Cancer Research Center. RSRT?s strong belief in collaborative research models has facilitated the sharing of data, cell lines and compounds amongst these labs that are now in regular communication. RSRT has awarded additional funding totaling $ 755,000 to two projects ongoing in the labs of Jeannie Lee, Ph.D., of Harvard and Antonio Bedalov, M.D., Ph.D., of Fred Hutchinson to aggressively pursue this work. ;

      ????RSRT funding will allow David Katz to generate a robust preclinical package for the drug, LM22A-4, which will include pharmacokinetic/pharmacodynamic, efficacy and safety data. Encouraging data will support a subsequent application to the FDA for an IND (Investigational New Drug). ;

      ????Successful fundraising on the part of the MECP2 Duplication Syndrome community facilitated two awards to Huda Zoghbi, M.D., Professor in the Departments of Pediatrics, Molecular and Human Genetics, Neurology and Neuroscience at Baylor College of Medicine and director of the Jan and Dan Duncan Neurological Research Institute, totaling $ 644,065. The funds will support two strategic approaches to treating the disorder. ; ; ?We are very excited to receive support for exploring two different strategies to reduce MeCP2 levels. The two strategies are complementary, one involving genetic screens in human cells to find potential targets that can be druggable with a pharmaceutical agent, while the other employs antisense oligonucleotides developed by Isis pharmaceuticals and designed to reduce MeCP2 levels directly,? said Dr. Zoghbi. ;

      ?Every dollar donated to RSRT can be tracked back to a family of an affected child and this family?s network of relatives, friends and colleagues. Our supporters around the world make our work possible and they have my immense appreciation. We are especially grateful to Reverse Rett (UK), Rett Syndrome Research & Treatment Foundation (Israel), and Girl Power 2 Cure. If you love a child with Rett or MECP2 Duplication Syndrome and find their current status quo unacceptable then I invite you to join us in our effort to end their immense suffering,? says Monica Coenraads, RSRT Executive Director and mother of an 18 year-old daughter with Rett Syndrome.

      ;

      Our partners in supporting this work are parents' organizations worldwide including Reverse Rett (UK), Rett Syndrome Research & Treatment Foundation (Israel), Skye Wellesley Foundation (UK), Rett Syndrome & CDKL5 Ireland, Rett Syndrom Deutschland, Stichting Rett Syndrome (Holland); and American organizations, Girl Power 2 Cure, Eva Fini Fund at RSRT, Kate Foundation for Rett Syndrome Research, Rocky Mountain Rett Association, Anastasi Fund, Claire?s Crusade, New Jersey Rett Syndrome Association, Rett Syndrome Association of Massachusetts, and the MECP2 Duplication Syndrome Fund at RSRT.

      ;

      List of 2014 Awards

      ;

      Clinical Trials ;
      Low-dose Ketamine for the Treatment of Rett Syndrome ;
      David Katz, Daniel Sessler, Tom Frazier, Sumit Parikh (Cleveland Clinic) ;
      $ 1,295,131 / 2 years

      ;

      Pharmacological Treatment of Rett Syndrome with 3-Hydroxy-3 ;
      methylglutaril-coenzyme A reductase Inhibitor-Lovastatin (Mevacor) ;
      Aleksandra Djukic (Children?s Hospital at Montefiore) ;
      $ 403,000 / 18 months

      ;

      Supplement for Copaxone Clinical Trial ;
      Aleksandra Djukic (Children?s Hospital at Montefiore) ;
      $ 47,000

      ;

      Awards ;
      Identifying Genetic Modifiers of MECP2 in the Mouse ;
      Monica Justice (Hospital for Sick Children, Toronto) ;
      $ 715,680 / 2 years

      ;

      Identification of Genetic Modifiers in Rett Syndrome ;
      Jeffrey Neul (Baylor College of Medicine) ;
      $ 314,456 / 2 years

      ;

      Re-awakening the Silenced Normal MECP2 Allele with Small Molecules to Treat Rett Syndrome ;
      Jeannie Lee (MGH/Harvard) ;
      $ 465,000 / 3 years

      ;

      Reactivation of Mecp2 on the Silent X ;
      Antonio Bedalov (Fred Hutchinson Cancer Research Institute) ;
      $ 290,000 / 1 year

      ;

      Preclinical Studies of LM22A-4 in Mouse Models of Rett Syndrome ;
      David Katz (Case Western) ;
      $ 272,000 / 2 years

      ;

      Testing Whether LM22A-4 Improves Hippocampal Function in Female MECP2 heterozygous mice ;
      Lucas Pozzo-Miller (University of Alabama Birmingham) ;
      $ 110,000 / 1 year

      ;

      Exploring the Link between MeCP2 and Gut Physiology to Test a Novel Probiotic Therapy for Rett Syndrome ;
      Ali Khoshnan, Sarkis Mazmanian (California Institute of Technology) ;
      $ 200,000 / 2 years

      ;

      NLX-101 as a Treatment for Breathing Disorders in Rett Syndrome ;
      Neurolixis ;
      $ 54,945 / 6 months

      ;

      Outlining the Autonomic Signature of Rett Syndrome ;
      Michael Carroll and Debra Weese-Mayer (Lurie Children?s Hospital of Chicago) ;
      $ 157,300 / 2 years

      ;

      Systems Genetics Approach toward Understanding Regulation of MECP2 Expression ;
      Terry Magnuson (University of North Carolina at Chapel Hill) ;
      $ 200,000 / 1 year

      ;

      High Content Phenotypic Screening of Existing Drugs for the Treatment of Rett Syndrome ;
      Recursion Pharmaceuticals ;
      $ 50,000 / 1 year

      ;

      MECP2 Consortium Supplement ;
      Gail Mandel, Michael Greenberg, Adrian Bird (OHSU, Harvard, University of Edinburgh) ;
      $ 250,000

      ;

      Supplement for Gene Therapy Consortium ;
      Steven Gray (UNC Chapel Hill) ;
      $ 67,401 / 2 years

      ;

      Life Sciences Research Foundation Fellow ;
      $ 91,500

      ;

      Tri-State Rett Syndrome at Montefiore ;
      Aleksandra Djukic ;
      $ 67,500

      ;

      Miscellaneous Pilot Studies ;
      $ 100,000

      ;

      MECP2 Duplication Syndrome ;
      Antisense Oligonulcleotide Therapy for the Treatment of MECP2 Duplication ;
      Huda Zoghbi (Baylor College of Medicine) ;
      $ 230,000 / 2 years

      ;

      A Forward Genetic Screen to Identify Druggable Modulators of MECP2 Levels ;
      Huda Zoghbi (Baylor College of Medicine) ;
      $ 414,065 / 2 years

      ;

      About Rett Syndrome ;
      Rett Syndrome is a genetic neurological disorder that almost exclusively affects girls. It strikes randomly, typically at the age of 12 to 18 months, and is caused by random mutations of the MECP2 gene on the X chromosome. Rett Syndrome is devastating as it deprives young girls of speech, hand use, and in most cases, normal movement and the ability to walk. As the girls enter childhood the disorder brings anxiety, seizures, tremors, and breathing difficulties. While their bodies suffer, it is believed that their cognitive abilities remain largely intact. Although most children survive to adulthood, they require total round-the-clock care.

      ;

      About the Rett Syndrome Research Trust ;
      RSRT is a non-profit organization with a highly focused and urgent mission: eradicate Rett Syndrome and related MECP2 disorders. In search of a cure and effective treatment options, RSRT operates at the center of global scientific activity, funding bold projects that are unlikely to be supported by the NIH or other more traditional funding agencies. RSRT refutes the conventional practice of labs working in isolation, instead seeking out, promoting and funding collaborations and consortia in which scientists work across multiple disciplines. These relationships enable the development and execution of a research agenda that neither academia nor industry could achieve alone. Since 2008, RSRT has provided $ 25 million in support of: 4 clinical trials testing 3 compounds, 33 scientists in 27 academic institutions and 3 biotech firms. To learn more about the Trust, please visit http://www.RSRT.org

      ; ; ; ; ;

        Enjoy Organic India's Premier Organic Teas and Supplements. Shop Now!

        Study: Herpes Vaccine in Development Shows Promise; CBCD Reviews a Report

        December 25, 2014 by  
        Filed under Allergy Tips

        Rochester, NY (PRWEB) December 25, 2014

        ?Infected with the herpes virus (HSV-1 or HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR.? - Greg Bennett, CBCD

        ;

        Dr. Ian Frazer, the scientist behind the HPV vaccine, Gardasil has scored a win with the results of a phase 1 herpes vaccine trial. A phase 1 vaccine trial is a closely monitored study trial of a new vaccine conducted in a small number of healthy volunteers, to determine safety in humans, metabolism, pharmacologic actions, and side effects at various doses. David Rhodes, the science officer of Australian healthcare group, Admedus, said ?the primary goal of the new vaccine was not to prevent the spread of herpes simplex but to treat it.? (1) Results of the study showed that the new herpes vaccine ?produced a T-cell response in 95 per cent of the humans it was tested in.? (1) T cells are killer immune system cells that detect cells infected with a virus and kill them. Importantly, the report noted that ?Over time the trials will be extended to test whether the vaccine also works to prevent the spread of the virus but this type of study takes a long period and must involve lots of people.? (1) The Center for the Biology of Chronic Disease (CBCD) reminds the public that FDA approval of vaccines takes time. Until Dr. Frazier?s new vaccine against HSV passes further testing and gains FDA approval, the CBCD recommends that HSV infected individuals take Novirin or Gene-Eden-VIR. The formula of these natural antiviral supplements was designed to help the immune system target the latent HSV.

        ;

        Click to learn more about herpes symptoms.

        ;

        The formula of Novirin and Gene-Eden-VIR was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes simplex virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, ?individuals infected with the HSV ? reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.? (2) The study authors also wrote that, ?we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.? (2)

        ;

        Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

        ;

        Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

        ;

        Regarding results of the phase 1 vaccine trial, Chief executive officer of Admedus, Lee Rodne, said: ?The very encouraging results, clean safety profile and cellular immune responses demonstrated in this HSV-2 study are particularly encouraging and validate the potential of our range of therapeutic vaccines which utilises Professor Frazer?s novel immunotherapy technology.? (See ProactiveInvestors.com.au, from October 2, 2014) (3)

        ;

        What treatments against genital herpes are currently on the market?

        ;

        ?Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.? (2)

        ;

        ?Until an effective vaccine becomes available, the CBCD recommends targeting the latent herpes virus with Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was shown to effectively reduce herpes symptoms in two separate post-marketing clinical studies.? - Greg Bennett, CBCD

        ;

        Click to learn more about Novirin and HSV and Gene-Eden-VIR and HSV.

        ;

        References:

        ;

        (1) news.com.au - "Professor Ian Frazer is developing vaccines for herpes simplex and cervical cancer." Published on October 03, 2014. ;
        http://www.news.com.au/lifestyle/health/professor-ian-frazer-is-developing-vaccines-for-herpes-simplex-and-cervical-cancer/story-fneuzlbd-1227078011314

        ;

        (2) Polansky, H., Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013. ;
        http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php

        ;

        (3) ProactiveInvestors.com.au - "Admedus vaccine for herpes has success; moves to next clinical trial." Published on October 2, 2014. ;
        http://www.proactiveinvestors.com.au/companies/news/57916/admedus-vaccine-for-herpes-has-success-moves-to-next-clinical-trial-57916.html

        ; ; ; ; ;

          Related Supplements Press Releases

          The Goddess Set

          Roy Ostenso Joins Vets Plus, Inc. for Product Line and Technology Development

          August 21, 2014 by  
          Filed under Allergy Tips

          Menomonie, WI (PRWEB) August 18, 2014

          Roy Ostenso has teamed with Vets Plus, Inc. as Project Manager for pet treats and jerky manufacturing. Ostenso brings extensive leadership experience to his role in product development for companion animals.

          ;

          Ostenso has over 20 years of experience in the computer hardware and software industry, having spent ten years as CEO/COO for TAPEDISK Corporation after positions in management and sales at several other software companies. He brings a strong history of product leadership to his role with the animal nutrition company. At Vets Plus, he is managing projects through the entire product development process from formulation to manufacturing to packaging. He focuses on new product lines and technology and improvements to current pet lines.

          ;

          Raj Lall, President and CEO of Vets Plus, Inc., said he admires Ostenso?s project leadership. He said, ?He?s working alongside our R&D and manufacturing teams to get our products market ready as quickly and efficiently as possible while maintaining our commitment to the research and quality of products.?

          ;

          Ostenso earned an MBA from the University of St. Thomas in St. Paul, Minn., and a BBA in Finance from University of Wisconsin-Eau Claire. He has served as President on the Board of Directors for the Dunn County Historical Society. He currently serves on the boards of the Dunn Co. Economic Development Corporation, Menomonie Tourism Commission, and the Wisconsin Council for Local History.

          ;

          About Vets Plus, Inc. ;
          Vets Plus, Inc. (VPI), located in Menomonie, Wisconsin, is a leading manufacturer of health and nutritional supplements for both food and companion animals. With over 20 years of experience, Vets Plus creates custom formulations for contract manufacturing of innovative probiotic, prebiotic, nutritional, and nutraceutical products in a wide variety of feeding forms. Vets Plus is proud of its continued growth into a leader within the animal health industry and ability to manufacture several hundred products while maintaining ISO-9001:2008 and NASC certifications and cGMP and AAFCO compliance. Vets Plus is a member of the American Pet Products Association (APPA).

          ;

          ; ; ; ; ;

            Organic Tulsi Formula

            Appilicious App Development Adds a Valuable Health Tool to Its Popular Diet App; the Ability to Add and Be Reminded of Daily Supplements

            July 21, 2014 by  
            Filed under Allergy Tips

            Austin, Texas (PRWEB) July 17, 2014

            Appilicious App development has updated the world?s first Dr. Simeons diet app, which debuted 2009 to now include the option to add in daily supplements. Appilicious wanted to re-engage their major audiences, which are; physicians and their patients, along with repeat Dr. Simeons diet app customers. The growth of the iPhone app market has driven the company to invest its resources in developing for the iTunes App Store platform.

            ;

            The Dr. Simeons diet community is growing steadily. This is due in part to the increase in the number of aesthetic offices nationwide realizing the cash positive benefit to administering his protocol. The number one reason physicians are on board with the process is because when followed, they have seen great weight loss success. Many patients have been losing between 18 and 25 pounds in one month eating organic low calorie meals and taking the prescribed injections. Appilicious? app has become a valuable tool, creating efficiency in following Dr. Simeons diet.

            ;

            Before the Dr. Simeons Diet App +, those going it alone had to use lengthy workbooks (imagine using that at the grocery store), physicians had to spend much of their day (or train additional staff) explaining the nuances of the diet over the phone which took away valuable office time to answer repeat questions. Before the company's App, protocol errors such as forgetting to record daily weight changes, double dosing of injections, and incorrect meal planning were prevalent and lead to weightless slowdowns and frustration.

            ;

            Appilicious? app serves the patient, giving the user discreet easy access to each detail. It streamlines the necessary daily tracking tasks through the creation of a simple check off system and intuitive food planning functionality. For physicians, it has reduced patient office visits, allowing doctors to increase patient pools. Many doctors require that the patient purchase our app as a prerequisite to coming in for their first consultation. The app can be set up and ready to go in just a few minutes. Everything the user needs from day 1 to completion is included. For these reasons it has become the standard in the marketplace.

            ;

            The app was updated with lessons learned recommendations from Dr. Edward E. Dickerson IV of Cape Fear Aesthetics. Dr. Dickerson, an efficacious double board certified surgeon, who first found personal success with the diet and went on to be a pioneer in creating an efficient and cutting-edge business model for operating Dr. Simeons protocol. The company took on the expertise of ?Dr. D? because their goal was to make sure that each customer could get a quality and reliable experience with the app. Because many of the users take supplements or have prescriptions, this was added to help people track all of their daily health tasks. They are prompted to take their supplements via pop ups when they add in each kind.

            ;

            Since the original diet was created in the 1970s, Appilicious asked Dr. D to help integrate modern changes. Updates addressed current societal health issues. Patients who are overweight suffer from high blood pressure and are diabetic, it was important that the user had a way to monitor this information daily. The Diet App + now has an easy to use blood pressure and glucose level tracking graph. The feature list continues to grow to better assist dieters to reach their weight-loss goals. Appilicious views these changes as a way to widen the appeal to physician-assisted dieters.

            ;

            The Diet App + is now available for $ 9.99 in the USA and is priced accordingly in other regions. The app is available for download to your android device and iPhone/iPad. The company is 100% committed to taking customer feedback to keep up with the unique demands of the marketplace. To find the app in iTunes or Google Marketplace, search: Appilicious.

            ;

            The Diet App + is developed by Appilicious, a mobile development company founded in 2010.

            ; ; ; ; ;

              Related Supplements Press Releases

              OrganicIndiaUSA.com

              Dr. Ajay Srivastava Brings 20 Years of Nutraceutical Research and Drug Development Experience to Vets Plus, Inc. Research and Development Team

              July 10, 2014 by  
              Filed under Allergy Tips

              Menomonie, Wis. (PRWEB) July 09, 2014

              Vets Plus, Inc. is pleased to announce Dr. Ajay Srivastava, DVM, Ph.D. has joined the Research and Development team as Director of Technical Services and Clinical Research. Dr. Srivastava will focus on research for companion animals.

              ;

              Dr. Srivastava was most recently Senior Research Scientist of the Anticonvulsant Drug Development Program at the University of Utah where he developed a novel animal model of pharmaco-resistant epilepsy to screen the potential antiepileptic drugs. Dr. Srivastava is one of the pioneer researchers on the role of antioxidants resveratrol and melatonin in epilepsy. He has 20 years of experience in drug development and nutraceutical research.

              ;

              Raj Lall, President and CEO of Vets Plus, Inc. said he is excited about the formulation and product development experience Dr. Srivastava brings to the position. ?Dr. Srivastava has a veterinary and pharmacology background and experience in clinical trials. He is an innovative thinker who will be a great addition to our research team.?

              ;

              Dr. Srivastava was recently invited to deliver a presentation on the benefits of nutraceuticals for cognitive health in aging pets at the National Animal Supplement Council (NASC) Annual Conference. At Vets Plus, he will focus on pre-clinical and clinical efficacy and safety studies of products for companion animals. He will be involved with product formulation and development, as well as literature review and technical support to customers and the sales team.

              ;

              After receiving his BS degree in biological sciences, Dr. Srivastava attended the School of Veterinary Medicine at GB Pant University of Agriculture and Technology in India before pursuing a master?s degree in Pharmacology. He continued his education, earning a Ph.D. in Neuropharmacology from All India Institute of Medical Sciences in New Delhi. He obtained his post-doctoral fellowship and advanced training in neuropharmacology at University of Utah, USA and certification in clinical research from National Institute of Health, USA.

              ;

              About Vets Plus, Inc. ;
              Vets Plus, Inc. (VPI), located in Menomonie, Wisconsin, is a leading manufacturer of health and nutritional supplements for both food and companion animals. With over 20 years of experience, Vets Plus creates custom formulations for contract manufacturing of innovative probiotic, prebiotic, nutritional, and nutraceutical products in a wide variety of feeding forms. Vets Plus is proud of its continued growth into a leader within the animal health industry and ability to manufacture several hundred products while maintaining ISO-9001:2008 and NASC certifications and cGMP and AAFCO compliance. Vets Plus is a member of the American Pet Products Association (APPA). ;

              ; ; ; ; ;

                Original Tulsi Tea

                Next Page »